Skip to main content

Table 3 Significant changes in individual questions of the SFNSL.

From: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study

Patient group

Question

Symptom subgroup

Change from baseline (mean ± SEM)

Significance*

ARA 290

6 (muscle cramps)

Frequency

−1.1 ±0.36

0.012

ARA 290

8 (chest pain)

Frequency

−0.5 ±0.19

0.026

ARA 290

12 (dry eyes)

Severity

−1.33 ±0.33

0.002

ARA 290

13 (blurred vision)

Severity

−1.17 ±0.32

0.004

ARA 290

14 (dizzy when rising)

Severity

−0.83 ± 0.32

0.025

ARA 290

21 (chest pain)

Severity

−0.58 ±0.19

0.012

Placebo

6 (muscle cramps)

Frequency

−0.7 ± 0.30

0.045

  1. *Determined by two-tailed paired ttest.